Texas Permanent School Fund Uni Qure N.V. Transaction History

Texas Permanent School Fund

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	SELL	$11.12 - $22.2 $845 - $1,687	-76 Reduced 0.21%	36,870 $422,000
Q1 2023 May 01, 2023	BUY	$18.7 - $23.07 $172,975 - $213,397	9,250 Added 33.4%	36,946 $744,000
Q4 2022 Feb 07, 2023	SELL	$18.12 - $27.32 $34,083 - $51,388	-1,881 Reduced 6.36%	27,696 $628,000
Q3 2022 Oct 25, 2022	BUY	$16.98 - $25.54 $58,326 - $87,729	3,435 Added 13.14%	29,577 $555,000
Q2 2022 Aug 08, 2022	BUY	$13.15 - $20.45 $7,705 - $11,983	586 Added 2.29%	26,142 $487,000
Q1 2022 May 06, 2022	SELL	$14.54 - $21.5 $6,194 - $9,159	-426 Reduced 1.64%	25,556 $462,000
Q4 2021 Feb 08, 2022	SELL	$20.24 - $36.01 $12,184 - $21,678	-602 Reduced 2.26%	25,982 $539,000
Q3 2021 Oct 28, 2021	BUY	$26.01 - $38.22 $691,449 - $1.02 Million	26,584 New	26,584 $851,000

154

40.4M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $712M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

Stay updated on Texas Permanent School Fund with notifications on news.